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Aberrant neuronal differentiation is 
common in glioma but is associated 
neither with epileptic seizures nor 
with better survival
Christoph Patrick Beier1,3, Tine Rasmussen1,2, Rikke Hedegaard Dahlrot4, Helene Broch Tenstad1,2, 
Julie Slinning Aarø1,2, Mai Froberg Sørensen1,2, Sólborg Berglind Heimisdóttir1,2, 
Mia Dahl Sørensen2,3, Per Svenningsen5, Markus J. Riemenschneider6, Dagmar Beier1,3 & 
Bjarne Winther Kristensen2,3
The mechanisms of glioma-associated seizures (GAS) have yet to be fully elucidated. Proneural subtype, 
isocitrate dehydrogenase 1 (IDH1) mutations, and epileptic seizures are closely associated suggesting 
that aberrant neuronal differentiation contributes to glioma-associated seizures. In a population-based 
cohort (n = 236), lack of stem cell marker expression (nestin, musashi) was significantly associated with 
IDH1 mutations and GAS at diagnosis. In vitro data suggested an association of IDH1 mutations and a 
more differentiated phenotype. Out of eight glioma stem cell (GSC) lines, seven revealed positivity for 
the synaptic marker protein synaptophysin. Three had synapse-like structures identified by electron 
microscopy and were either vGlut1 (glutamatergic) or GAD67 (GABAergic) positive. In vivo, >10% 
synaptophysin-positive tumour cells were present in >90% of all gliomas. Synaptophysin expression 
was associated with proneural subtype and vGlut1 expression, suggesting that most synapse-like 
structures in glioma are glutamatergic. However, we found null associations between vGlut1 protein/
mRNA expression and survival, GAS at onset, development of GAS after resection, and refractory 
GAS. Synapse-like structures were neither functional nor activated by spontaneous action potentials 
or cellular networks. Thus, aberrant neuronal differentiation including glutamatergic synapse-like 
structures is detectable in glioma but is associated neither with epileptic seizures nor with better 
survival.
The treatment and prognosis of patients diagnosed with glioma of all grades has been improved in the last two 
decades, e.g. due to the introduction of temozolomide as standard of care for glioblastomas (GBM)1 and the com-
bination of radiotherapy and chemotherapy with procarbacin/lomustine/vincristine in low-grade glioma2. The 
number of long-term survivors has accordingly increased and the management of neurological symptoms will 
therefore become increasingly important in these patients.
Epileptic seizures substantially interfere with the quality of life of glioma patients, especially long-term survi-
vors, irrespective of tumour grade, and are strongly associated with neuropsychological deficits3,4. Glioma differs 
from other kinds of brain tumours due to its increased epileptogenicity with up to 80% of patients suffering 
from epileptic seizures. There is a substantial lack of valuable epidemiological data, but clinical experience and 
all available data clearly suggest that the risk of developing seizures is substantially higher in patients with gli-
oma as compared to patients with other kinds of non-glial brain tumours, likely due to glioma-specific mech-
anisms of epileptogenesis5. Although several mechanisms have been proposed to explain tumour-associated 
seizures, the imbalance between excitatory glutamatergic drive and impaired or defect GABAergic inhibition 
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appears to be the crucial mechanism of glioma-associated seizures6. On one hand, the balance of glutamate and 
GABA is affected by reduced chloride potassium symporter KCC2 and increased Na-K-Cl cotransporter NKCC1 
expression in the peritumoural tissue, resulting in inverse chloride homeostasis and GABAergic cortical excita-
tion7. On the other hand, extracellular glutamate concentrations are increased in glioma patients. Three major 
mechanisms regulate glutamate secretion in the CNS8: vesicular secretion via neuronal synapses, non-vesicular 
secretion via the Xc-cystine glutamate transporter (SLC7A11, xCT), and glutamate clearance via aminoacid 
transporters (EAAT1/2). Increased expression of xCT and decreased expression of EAAT1/2 are both associ-
ated with increased glutamate concentrations in the cerebrospinal fluid, which is an independent predictor of 
glioma-associated seizures (GAS)9. Substantial additional experimental evidence suggests an important role of 
xCT in GAS10,11. However, xCT expression is only associated with GAS at diagnosis but neither with refractory 
seizures nor with the development of seizures after resection12. This stresses the need for identification of con-
tributing factors causing GAS. So far, it is yet unknown, if vesicular glutamate secretion also contributes to GAS.
Mutations of isocitrate dehydrogenase 1 (IDH1) and rarely of isocitrate dehydrogenase 2 (IDH2), are driver 
mutations of low-grade glioma and secondary glioblastoma (GBM)13,14 and associated with both seizures and 
better outcome. The molecular mechanism of the strong and reproducible association of IDH1 mutations and 
epileptic seizures remains unclear15–17. Chen et al. could recently show that D-2-hydroxyglutarate (D2HG), the 
product of mutant IDH1, is able to directly activate N-methyl-D-aspartate (NMDA) receptors. Although this pro-
vides an elegant explanation for the increased epileptogenicity of IDH1 mutant glioma, the D2HG concentrations 
needed for activation of NMDA receptors in vitro (10 mM) have been higher than the actual D2HG concentra-
tions measured in the CNS of patients (1–6 mM)16,18.
Mutations of IDH1 are associated with better outcome, substantially increased risk of developing epileptic 
seizures, and cause a CPG-island hypermethylation phenotype that is associated with the proneural subtype of 
glioma19,20. The association of outcome, epileptic seizures, IDH1 mutations and the proneural phenotype suggests 
a pathophysiological link between the factors, especially between proneural differentiation and epileptic seizures. 
Further evidence supporting the hypothesis that neural differentiation causes seizures came from a study inves-
tigating the association of the synaptic protein SV2 and the response of GAS to anti-epileptic treatment with 
levetiracetam (that specifically binds to SV2A). Unexpectedly, the expression of the synaptic protein SV2A in bulk 
tumour cells showed an even stronger association with response to levetiracetam than SV2A expression in the 
infiltration zone, suggesting that neuronal structures within the tumour contribute to epileptogenesis.
In patients, the expression of neuronal markers in glioma remained without prognostic significance in two 
retrospective cohort studies21,22]. Classical serum-cultivated glioma cell lines did not express neuronal markers, 
and neuronal differentiation in vitro was not yet studied in detail. Therefore, we used glioma stem cells (GSC) 
maintaining the ability to differentiate into cells expressing markers of all three neural lineages23–25 to study neu-
ronal differentiation of glioma cells and its association with IDH1 mutations, outcome, and epileptic seizures.
Results
Nestin is not an independent prognostic factor for epileptic seizures but associated with IDH1 
R132 mutations. We studied the association of the stem cell markers nestin and musashi-1 with epileptic 
seizures at diagnosis in a cohort comprising 239 patients with gliomas (WHO II-IV, overview over patients: 
Supplementary Table 1, previously reported in26). IDH R132H mutation was strongly associated with seizures 
at onset (Fig. 1A). High nestin and high musashi-1 expression were associated with WHO grade (Fig. 1B, 
Supplementary Fig. 1A) and IDHwildtype (Fig. 1C, Supplementary Fig. 1B). IDH R132H mutation and low 
WHO grade showed a strong and significant association with epileptic seizures at diagnosis (Supplementary 
Table 2). In contrast, nestin and musashi-1 expression were associated inversely with epileptic seizures (Fig. 1D, 
Supplementary Fig. 1C, Supplementary Table 2). Due to the assumed interaction of IDH1 mutation, WHO grade 
and nestin expression, we performed a multi-variate analysis to identify crucial contributors among the three 
factors associated with epileptic seizures. Logistic regression showed that only IDH1 R132 mutations but neither 
nestin expression nor WHO grade remained independently associated with seizures at diagnosis (Supplementary 
Table 3).
IDH1 mutations in glioma are associated with a more differentiated phenotype in vitro. From 
a previously studied cohort of >70 glioma patients23,27,28, data on IDH status was available for 42 patients 
(Supplementary Table 4). IDH1 mutated tumours did not show persistent growth of GSC in vitro (Fig. 1E,F) and 
had significantly lower nestin expression (Fig. 1G). The spontaneous in vitro differentiation pattern (passage 1, 
direct after resection) was available from 7 tumours. First passage glioma cells from tumours with IDH1 R132H 
mutations showed a more restricted differentiation pattern as compared to wildtype gliomas and almost exclu-
sively expressed markers of oligodendrocytes and neurons (Fig. 1G).
Expression of markers indicating neuronal differentiation in GSC lines. We hypothesized that the 
more differentiated phenotype of IDH1R132H glioma may contribute to their higher epileptogenicity. We therefore 
studied the spontaneous aberrant neuronal marker expression in seven primary GSC lines from two different 
laboratories (CPB and BWK)23–25. All GSC lines were cultured using serum-free medium supplemented with EGF 
and FGF. Cells from all GSC lines expressed markers of neuronal (NeuN, beta-3-tubulin) differentiation to a cer-
tain degree. In three GSC lines (R11, R28, T111) a subset of cells showed a strong and consistent neuronal marker 
expression pattern. They expressed markers for immature neurons (beta-3-tubulin), markers for mature neurons 
(NeuN) and markers indicative for synapses (synaptophysin, SV2A, Fig. 2, Supplementary Fig. 2, Table 1). The 
expression pattern was inconsistent in four GSC lines (Table 1).
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Synapse-like structure within GSC lines in vitro. We found cell-cell contacts with strong positivity for 
the pan-synaptic markerprotein synaptophysin suggesting synapse-like structures (Fig. 3A) in two GSC lines 
(R11 and R28 but not in the GSC line T111). Culture conditions known to foster neuronal differentiation in neu-
ronal stem cells (growth factor deprivation, 1% serum, 0.1% retinoic acid), significantly increased the number of 
synaptophysin positive cell-cell contacts (Fig. 3B). To verify that these synaptophysin-positive cell-cell contacts 
correspond to synapse-like structures, we used electronmicroscopy of GSC cultured as spheres under standard 
conditions. Culturing of GSC lines as spheres allows the analysis of the direct interaction of glioma cells. The three 
GSC lines with substantial neuronal differentiation but none of the other GSC lines showed structures resembling 
synaptic vesicles. The GSC lines R11 and R28 that had spontaneous synaptophysin-positive cell-cell contacts also 
showed microstructures reminiscent to synapses (Fig. 3C, Table 1).
Figure 1. IDH1 wildtype status positively correlates with tumour stem cell properties. (A) The risk of seizures 
at onset is associated with IDH1 R132H mutations (*p < 0.05, chi2-test). (B,C) Distribution of WHO grade 
(B) and IDH mutation status (C) in glioma with high and low nestin expression (above and below median, 
*p < 0.05, chi2-test). (D) Seizures at onset in tumours with nestin expression above and below median 
(*p < 0.05, chi2-test). (E,F) Representative images illustrating lineage-restricted progenitor cell-like (to the 
left, R47) and neurosphere-like growth (to the right, R28, 25-fold magnification each). IDH mutation status 
correlates with the ability to form neurospheres. (***p < 0.0002, chi2-test). (G) The differentiation pattern of 
first-passage tumour cell cultures of three gliomas with IDH R132H (R26, R24, R42) mutations and four IDH 
wildtype gliomas (R11, R18, R22, R28) are given (**p = 0.0004, *p = 0.005, two-sided student’s t-test).
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Synapse-like structures within GSC lines in vivo and in human glioma. To exclude that the 
synapse-like structures correspond to a cell culture artefact, we further analyzed tumour material from xenograft 
tumours from the GSC lines R8 (slightly synaptophysin positive) and the GSC line R28 (strongly synaptophysin 
positive). Both xenograft tumours showed substantial positivity for human synaptophysin mainly in the invasion 
zone and in the boundaries of the tumours (Fig. 4A). To further confirm the presence of synaptophysin-positive 
glioma cells in vivo, we used a tissue-microarray including three IDH1 positive gliomas. Three out of six tumours 
were strongly positive for synaptophysin, three were negative (Fig. 4B).
Synaptophysin expression was also common in IDHwildtype glioblastoma. In a cohort of 40 samples, 29 out of 
40 IDHwildtype tumours expressed synaptophysin (Fig. 4C). Immunostaining with histological markers indicative 
for the proneural and mesenchymal subtype (described in29) showed, a significant association with the proneural 
subtype but synaptophysin was also detectable in mesenchymal GBM (Fig. 4D). There was no association of epi-
leptic seizures with proneural phenotype or synaptophysin expression (Fig. 4E,F).
Figure 2. Expression of markers of neuronal differentiation. The entire panel of GSC lines was stained for 
SV2A, NeuN, vGlut1, GAD67 and synaptophysin. Representative staining of each marker from the GSC line 
R28 are shown. Single cells are shown with higher magnification in the inset given in the left upper corner. 
DAPI counterstaining was used to visualize nuclei.
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Synapse-like structures within GSC lines may be glutamatergic or GABAergic. Glutamate (excit-
atory) and GABA (inhibitory) are the two most important neurotransmitters in the human brain. To detect gluta-
matergic synapses, we used the well-establish marker protein vGlut1 (SLC17A7), which is a vesicular protein that 
transports glutamate into the synaptic vesicle. In our panel of seven GSC lines, three expressed vGlut1. Another 
four were positive for GAD67, the crucial protein in the biosynthesis of GABA and an established marker for 
GABAergic neurons (Fig. 5A). One of the GAD67 positive GSC lines was also positive for vGlut1, however, none 
of the GAD67-positive GSC lines studied had detectable synapse-like structures when studied using electron 
Beta-tubulin Synapto-physin SV2A vGlut1 NeuN GAD67
Synapse-like 
structure EM
R8 + (+) ++ − − ++ (−)
R11 +++ +++ +++ + − (+) +
R18 + (+) + − − +++ (+)
R28 ++ +++ + ++ + + ++
T78 + (+) n.a. − (+) ++ −
T87 − + n.a. − − (+) (+)
T111 + + +++ − ++ ++ (+)
Murine NSC + n.a. ++ n.a. ++ ++
Table 1. Markers of neuronal differentiation in a panel of GSC lines. Legend: Immunocytochemistry: −No 
staining. (+) few cells/low staining intensity + clear positivity ++ − +++ strong/very strong staining intensity. 
Electronmicroscopy: −No structures reminiscent to synapses. (+) vesicles + synapses ++ many synapses.
Figure 3. Synapse-like structures within GSC lines. (A) DAPI, synaptophysin (high and low magnification), 
phasecontrast and β-III tubulin staining of GSC line R28 is shown. (B) Number of synaptophysin-positive cell-
cell contacts under standard culture conditions (serum free medium supplemented with EGF/FGF/B27) and 
under conditions favoring neuronal differentiation (no growth factors, 1% serum, 0.1% retinoic acid, p < 0.005, 
student’s-t-test). (C) Electronmicroscopy of GSC spheres cultured under standard conditions. Synapse-like 
structures are shown in higher magnification on the right side.
www.nature.com/scientificreports/
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Figure 4. Synapse-like structures in vivo. (A) Immunostaining detecting human synaptophysin in xenograft 
tumours (R8, R28). (B) Synaptophysin immunostaining (left side) and IDH1 immunostaining (right side) 
of a tissue microarray containing WHO grade 2 tumours (2) and WHO grade 3 tumour (3), cerebellum as 
positive control (C), and intestine as negative control (IT) for the synaptophysin staining. (C) Representative 
synaptophysin immunostaining of human IDH wildtype glioblastoma samples with high (left) and low 
synaptophysin expression (right). (D) Correlation of synaptophysin expression with markers indicative for 
proneural (proneural-mesenchymal score >0) and the mesenchymal subtype (proneural-mesenchymal score 
<0, Pearson r = 0.3, p = 0.05). (E) Association of epileptic seizures and markers indicative for proneural 
(proneural-mesenchymal score >0) and the mesenchymal subtype (proneural-mesenchymal score <0 (p = 0.3, 
Mann-Whitney U-test). (F) Association of synaptophysin expression with epileptic seizures (p = 0.9, Mann-
Whitney U-test).
www.nature.com/scientificreports/
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microscopy (Table 1). Notably, all GSC lines expressed the synaptic protein SV2A, which binds to levetiracetam, 
to some extent. SV2A was expressed in both glutamatergic and GABAergic synapses and varied substantially 
between the GSC lines. The classical, serum cultured glioma cells lines like T98G or U87 as well as the breast 
cancer cell lines MCF7 did not express SV2A (Fig. 5B). In vitro, the vesicular transporter vGlut1 co-localized with 
synaptophysin in both double-positive GSC lines (Fig. 5C). In vivo, vGlut1 mRNA expression correlated very 
strongly with synaptophysin expression in microarrays available to the RemBraNDT (REpository for Molecular 
BRAin Neoplasia DaTa) database (Pearson r = 0.92, p < 0.001, Fig. 5D). In contrast, expression of GAD67 mRNA 
was less associated with synaptophysin mRNA expression (Pearson r = 0.36, p < 0.001, Fig. 5E). Analysis of the 
TCGA database available at the same repository gave similar results (Synaptophysin/vGlut1: Pearson r = 0.85, 
synaptphysin/GAD67: Pearson r = 0.38).
Lack of association of vGlut1 expression and epileptic seizures. Given that glutamate is the strong-
est and most common excitatory neurotransmitter in the human brain, we hypothesized that neuronal differ-
entiation with a “glutamateric phenotype” may contribute to GAS. We therefore studied a large, representative 
Figure 5. Glutamatergic and GABAergic glioma cells. (A,B) Westernblot of GSC lines and control samples 
(breast cancer cell line MCF7, classical glioma cell lines T98G, U87). Blots were probed with antibodies against 
GAD67, synaptophysin, SV2A and vGlut1. Actin was used as loading control. (C) Immunocytochemistry 
against vGlut1 and synaptophysin. DAPI was used to label the nuclei. (D,E) Correlation of synaptophysin 
expression with vGlut1 (Pearson r = 0.92, p < 0.001) and GAD67 (Pearson r = 0.36, p = 0.001) using mRNA 
expression data from the RemBranDT database (accessed: 09 January 2018).
www.nature.com/scientificreports/
8SCieNtifiC RepoRtS |  (2018) 8:14965  | DOI:10.1038/s41598-018-33282-5
cohort of 224 patients for vGlut1 expression and seizures at onset (Patients characteristics: Supplementary 
Table 5). However, the expression of vGlut1 was neither associated with IDH1 status nor with tumour grade (data 
not shown). Further, we found no association with seizures at onset (Fig. 6A), development of seizures at any 
time point (Fig. 6B), or survival (Fig. 6C). vGlut1 expression was associated with MGMT methylation pattern 
(Fig. 6D).
GSC lines with marked neuronal differentiation are not excitable and do not show spontane-
ous action potentials. To further understand why these vesicular structures filled with glutamate did not 
influence the odds for developing epileptic seizures, we studied if glioma cells with neuronal differentiation are 
able to release glutamate. In mature neurons, synaptic release of glutamate is triggered by calcium influx due to 
voltage-dependent calcium channels. We therefore studied intracellular calcium levels using Fluo4. Time-lapse 
imaging in a cell culture incubator with stable temperature and oxygen concentrations revealed that five out of 
six GSC lines studied showed spontaneous calcium changes in intracellular calcium concentrations that were not 
seen in the breast cancer cell lines MCF7 (Fig. 6E, Supplementary Film 1). The membrane potentials in single R28 
cells were depolarized (−28 ± 5 mV, n = 4) and stable, indicating that the changes in intracellular calcium were 
not due to spontaneous action potentials (data not shown). Moreover, the changes in intracellular calcium were 
not consistently inhibited or induced by high potassium concentration (data not shown) and the analysis of close 
adjacent cells clearly indicated that glioma cells did neither create cellular networks nor consistently modified 
calcium levels in neighbouring cells (Supplementary Film 2).
Figure 6. Association of vGlut1 expression with clinical characteristics. (A,B) Risk of seizures at onset (A) 
and at any time point during disease (B) in patients with high, intermediate, low and no vGlut1 expression. (C) 
Survival of patients with high, intermediate, low and no vGlut1 expression (p = 7., Log-Rank test). (D) MGMT 
methylation status in patients with high, intermediate, low and no vGlut1 expression. (E) Proportion of cells 
with spontaneous changing intracellular calcium concentrations within 5 min periods.
www.nature.com/scientificreports/
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Discussion
Aberrant neuronal marker expression - alone or in combination with glial markers - is well established in GSC lines 
and was also observed in vivo21,23,24,30. We here provide evidence that a subset of glioma cells display more advanced 
neuronal differentiation in vitro and in vivo that went beyond aberrant marker expression but included synapse-like 
structures with the ability to generate non-functional synapse-like direct cell-cell contacts among glioma cells.
Our data did not substantiate the hypothesis that the (pro-)neural differentiation was crucial for or at least 
contributed to GAS. We challenged the hypothesis using several approaches (e.g. association of proneural phe-
notype and seizures in IDHwildtype GBM), correlation of synaptophysin and seizures in IDHwildtype GBM). None of 
the results supported the hypothesis. We therefore only focused on gliomas with a glutamatergic differentiation 
but did not find any association with seizures either. Given that the proneural phenotype is associated with the 
polymethylator-phenotype19, the identified association of neuronal differentiation, glutamatergic synapse-like 
structures, and MGMT methylation was expected. In summary, the provided data falsified the working hypoth-
esis. For obvious reasons, it is impossible to exclude a yet unknown mechanism associated with neuronal differ-
entiation and contributing to GAS in minor subgroups within the different cohorts studied. However, because we 
did not find consistent or suggestive trends in our data in support of the working hypothesis, we do not assume 
having overlooked a biological relevant effect.
Our data suggests that proneural differentiation and GAS are both secondary to IDH1 R132H gain-of-function 
mutations. The most plausible explanation for GAS in IDHR132H glioma is directed stimulation of NMDA recep-
tors by D2HG16. We assume that neuronal differentiation is likely secondary to the epigenetic changes resulting 
from D2HG induced hypermethylation as suggested by data from Noushmehr et al.19. In line with other studies, 
we did not find a prognostic relevance of neuronal differentiation as indicated by vGlut1 expression21,22.
Although our data consistently falsify the working hypothesis, the amount and degree of neuronal differenti-
ation within glioma was surprising. Here we describe and characterize for the first time synapse-like structures 
within glioma cells in vitro and in vivo. The GSC lines with consistent neuronal differentiation used for our exper-
iments have been derived from typical primary GBM and were able to form GBM-like lesions after transplanta-
tion into nude mice23,29,31. By choosing GSC lines from two laboratories, we reduced the risk of contamination 
or other technical artefacts. The biological significance of this neuronal differentiation remains unknown and 
the results of several experiments were unanticipated (e.g. expression of synaptophysin in the invasion zone of 
xenotransplants only). It may represent an epiphenomenon that indicates that the cells of origin of GBM as well as 
the stem cell-like tumour cells (“cancer stem cells”) driving tumour growth are pluripotent with a variable degree 
of neuronal differentiation. This would be in line with a recent study using a murine glioma model describing that 
all glioma derive from proneural progenitors32. From a broader perspective, it is likely that we characterized the 
cellular correlate to the proneural/neural glioma subtype identified in the context of several large-scale attempts 
to subclassify glioma19,20,28,33–35. As in our study, the translational significance of the different subtypes identi-
fied in the last decade remains vague despite evidence suggesting some importance for treatment response36–39. 
Although we did not assess the molecular status of the glioma samples used in detail, it appears likely that the 
assumed higher incidence of seizures in proneural glioma is secondary to IDH mutations and therefore adds GAS 
to the list of clinical features not associated with the molecular well-defined subtypes.
In summary, our study provides evidence suggestive for the existence of an advanced neuronal differentiation 
of glioma cells and showed that neuronal differentiation of glioma cells is associated neither with survival nor 
with seizures at onset.
Material and Methods
Patient cohorts. Cohort Fig. 1 and Supplementary Fig. 1: This retrospective study examined all adult 
patients with newly diagnosed glioma in the Region of Southern Denmark between 2005 and 2009 (n = 433). 
For 239 of these patients, sufficient tumour tissue was available. The histological diagnosis was made using the 
2007 WHO criteria40. Three patients with WHO grade 1 glioma were excluded. Data on seizures at onset were 
available for all patients. The patient cohort and nestin staining has been published previously26 (Ethic Committee 
approval: S2DO90o80, Danish Data Protection Agency: 2009-41-3070). All experiments in this paper with 
patient material/data were performed in accordance with relevant national and local guidelines and regulations.
Cohort Fig. 4D: This retrospective study examined patients diagnosed with adult IDHwildtype GBM at Odense 
University Hospital between January 2009 and December 2012 (n = 40). The GBM were chosen consecutively by 
starting at the last patient diagnosed in 2012 and going backwards until we had a total of 40 patients (Ethic com-
mittee approval: S-20110022, Danish Data Protection Agency: 16/32269).
Cohort Fig. 6: The cohort includes all consecutive glioma samples resected in the Department of Neurosurgery, 
Odense University Hospital, with sufficient high quality material for tissue microarrays. The histological diagno-
sis was made using the 2007 WHO criteria40. Demographic and survival data, data on seizures at onset, develop-
ment of seizures at any time point, data on molecular markers (methyl-guanidin-methyl-transferase (MGMT) 
promoter, IDH1 status) were systematically assessed based on the patients records. In the same cohort, expression 
of xCT was determined, which was published elsewhere41 (Ethic committee approval:. S-20150148, Danish Data 
Protection Agency: 16/32269).
Generation of GSC lines. Between 2005 and 2010, >70 GSC lines have been established and characterized 
using tumour samples from glioma WHO grade 2-4.23,27,28. This was approved by the local ethics committee (no: 
05/105, University of Regensburg, Germany). The preparation of GSC lines was previously described in23,25. In 
brief, fresh tumour material was dissociated into a single cell suspension and the cells were seeded in serum-free 
medium supplemented with 20 ng/ml EGF and FGF in addition to LIF and B27 supplement. GSC lines were 
cultured at least 4 weeks and the growth pattern was analyzed at least once a week. The growth pattern described 
refers to the initial growth pattern of GSC lines during the first 5 passages. Generation of GSC lines T111 and T78 
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were previously described42. For all other experiments, GSC lines were cultured in serum-free medium supple-
mented with 20 ng/ml EGF, 20 ng/ml FGF, and 1% B27 supplement.
Histology. The IDH1 status of the GSC lines was determined by sequencing as described in43. In all other 
experiments, the IDH R132H mutation was detected as previously described44 using the mIDH1R132H antibody 
(mIDH1R132H, clone H14, Dionova, 1:100).
Nestin and musashi-1 positive tumour cells were identified as previously described (nestin 196908 anti-
body, R&D systems (1:100) and musashi-1 clone 14H1, MBL International, 1:200)26,45. Slides were stained on 
the AutostainerPlus platform (Dako, Glostrup, Denmark) and DyLight 650 (1 + 100 Fisher Scientific) was used 
for detection of nestin. The fraction of nestin positive tumour cells was identified using quantitative image 
analysis with continuous estimates of staining in the Visiomorph module of the Visiopharm Integrator System 
(Visiopharm, Hørsholm, Denmark).
Three-micrometer sections of paraffin-embedded GBM samples were stained using synaptophysin antibody 
from NovoCastra (NCL-SYNAP-299, clone 27G12, 1:50) on an automated immunostainer (BenchMark Ultra 
IHC/ISH staining system, Ventana Medical Systems, USA). OLIG2, NeuN, DLL3, YKL40, CD44, and VEGF were 
stained as described in detail in46. All samples were scored blinded (MFS, SBH). Synaptophysin was evaluated 
with respect to antigen expression alone, and scored from 0–100 according to percent positivity. OLIG2, NeuN, 
DLL3, YKL40, CD44, and VEGF was scored as described in29. In brief, 5 positions per slide were scored from 
each marker (0: no expression; 1: <10% expression; 2: 10%–49% expression, 3: 50%–90%, 4: >90%). The sum 
of the means of the mesenchymal markers was subtracted from the sum of the means of the proneural markers.
In vivo tumour model. The tumour model was described previously, in brief 50.000-100.000 tumours cells 
were suspended in 2 µl saline and injected intracranially injected into T-lymphocyte-deficient NMRI mice as 
described in23,31. The procederes were conducted in accordance with German law governing animal care and 
approved by the local authorities (Az. 621-2531.1-04/03, Regierung der Oberpfalz, Germany). 10 µm slides were 
stained against synaptophysin (NovoCastra (NCL-SYNAP-299, clone 27G12, 1:100) and counter stained with 
H&E using standard protocols.
Immunocytochemistry. Immunocytochemistry of glioma cells plated on cover slips coated with 
poly-ornithine and laminin was performed as described in28. The following antibodies were used in a dilu-
tion of 1:100 if not otherwise specified: beta-3-tubulin: Promega G7121 (1:1000), GFAP: DAKO Z 0334, 
Nestin: Chemicon MAB5326 (1:500), NeuN: Chemicon MAD377 (1:50), SVA2: Abcam ab49572 (1:100), 
GAD67: ThermoFisher PA1-37733 (1:100), vGlut1: Abcam ab193595 (1:100), synaptophysin: Novacastra 
NCL-SYNAP-299 (1:50).
Electronmicroscopy. Electronmicroscopy was performed according to standard procedures in the 
Department of Pathology, Odense University Hospital. In brief, cells were centrifuged, washed using 0.1 phos-
phatbuffer and fixed using 2% glutaraldehyd. After fixation, pellets were stained using 1% osmiumtetraoxid and 
embedded in epoxy and analyzed using JEOL JEM-1400 electronmicroscope.
Westernblot. Westernblots were performed according standard procedures. The following antibodies 
were used for probing: beta-actin: Sigma A5441 (1:1000), Promega G7121, SVA2: Abcam ab49572 (1:1000), 
GAD67: ThermoFisher PA1-37733 (1:1000), vGlut1: Abcam ab193595 (1:1000), synaptophysin: Novacastra 
NCL-SYNAP-299 (1:1000).
Current Clamp. Membrane potentials in GSC cells were recorded using the current-clamp mode of the 
Axopatch-amplifier (Axon Instruments, Foster City, CA, USA) and the Clampex 9.2 data acquisition software (Axon 
Instruments). Membrane potentials was measured after obtaining the whole-cell configuration and measured for min-
utes to test for spontaneous changes. The solution in the pipette was (in mmol/l): 135 K-glutamate; 10 KCl; 10 NaCl; 1 
MgCl2; 10 HEPES; 0.3 NaGTP; 0.5 MgATP and 2 EGTA. Bath solution was (in mmol/l): 10 HEPES-NaOH, 140 NaCl, 
2.8, KCl, 1 MgCl2, 2 CaCl2, 11 glucose, and 10 sucrose. Experiments were performed at room temperature.
Microarray analysis. We used the publically available Repository for Molecular BRAin Neoplasia DaTa 
(REMBRANDT, http://www.betastasis.com/glioma/rembrandt/) that is based on 524 Affymatrix U133 2.0 plus 
microarrays to investigate the correlation of vGlut1 and synaptophysin expression. The databased was accessed 
09 January 2018 and data was analysed using SPSS 24.0.
Statistics. All statistical analyses were performed used SPSS 24.0. The statistical test used is given in the leg-
end to the respective Figures.
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